Easywell Biomedicals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 10, 2022
Share
Easywell Biomedicals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 42.06 million compared to TWD 42.01 million a year ago. Net loss was TWD 25.78 million compared to TWD 50.43 million a year ago. Basic loss per share from continuing operations was TWD 0.23 compared to TWD 0.44 a year ago.
For the nine months, sales was TWD 112.05 million compared to TWD 160.18 million a year ago. Net loss was TWD 115.29 million compared to TWD 106.81 million a year ago. Basic loss per share from continuing operations was TWD 1.01 compared to TWD 1.08 a year ago.
Easywell Biomedicals Inc. is a Taiwan-based company principally engaged in the research, development, production and sale of raw materials and temperature measurement products. The raw materials are applied in the manufacture of medicament for the treatment of epilepsy, pain and fever, antihypertensive and diuretic, skeletal muscle relaxants, among others. The Company's diagnostic devices include ear thermometers and digital clinical thermometers. The Company distributes its products mainly in Taiwan, the Americas and Europe.
EASYWELL BIOMEDICALS, INC. 
